Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1974 1
1975 2
1976 3
1977 4
1978 4
1979 4
1980 4
1981 1
1982 9
1983 5
1984 5
1985 11
1986 8
1987 8
1988 10
1989 26
1990 7
1991 24
1992 15
1993 21
1994 16
1995 18
1996 13
1997 25
1998 19
1999 20
2000 25
2001 19
2002 22
2003 43
2004 20
2005 32
2006 30
2007 38
2008 29
2009 39
2010 45
2011 48
2012 52
2013 52
2014 66
2015 55
2016 63
2017 65
2018 62
2019 81
2020 77
2021 66
2022 58
2023 51
2024 27

Text availability

Article attribute

Article type

Publication date

Search Results

1,281 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Malignant Neoplasm of Multiple Primary Sites"
Page 1
Gastroenteropancreatic Neuroendocrine Tumors.
Cives M, Strosberg JR. Cives M, et al. CA Cancer J Clin. 2018 Nov;68(6):471-487. doi: 10.3322/caac.21493. Epub 2018 Oct 8. CA Cancer J Clin. 2018. PMID: 30295930 Free article. Review.
Fundamental biologic and genomic differences underlie the clinical heterogeneity of NETs, and distinct molecular features characterize NETs of different grades and different primary sites. Although surgery remains the cornerstone of treatment for localized tumors, s …
Fundamental biologic and genomic differences underlie the clinical heterogeneity of NETs, and distinct molecular features characterize NETs …
Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis.
Miettinen M, Lasota J. Miettinen M, et al. Arch Pathol Lab Med. 2006 Oct;130(10):1466-78. doi: 10.5858/2006-130-1466-GSTROM. Arch Pathol Lab Med. 2006. PMID: 17090188 Free article. Review.
CONCLUSIONS: GISTs usually occur in older adults (median age 55-60 years) and rarely in children in the second decade (<1%) throughout the gastrointestinal tract: 60% in stomach, 35% in small intestine, and less than 5% in rectum, esophagus, omentum, and mesentery; most GISTs …
CONCLUSIONS: GISTs usually occur in older adults (median age 55-60 years) and rarely in children in the second decade (<1%) throughout th …
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors.
Patel SP, Othus M, Chae YK, Giles FJ, Hansel DE, Singh PP, Fontaine A, Shah MH, Kasi A, Baghdadi TA, Matrana M, Gatalica Z, Korn WM, Hayward J, McLeod C, Chen HX, Sharon E, Mayerson E, Ryan CW, Plets M, Blanke CD, Kurzrock R. Patel SP, et al. Clin Cancer Res. 2020 May 15;26(10):2290-2296. doi: 10.1158/1078-0432.CCR-19-3356. Epub 2020 Jan 22. Clin Cancer Res. 2020. PMID: 31969335 Free PMC article. Clinical Trial.
We report the results of the (nonpancreatic) neuroendocrine neoplasm cohort of SWOG S1609 dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART). ...RESULTS: Thirty-two eligible patients received therapy; 18 (56%) had high-grade disease. Most common primary …
We report the results of the (nonpancreatic) neuroendocrine neoplasm cohort of SWOG S1609 dual anti-CTLA-4 and anti-PD-1 blockade in …
Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2).
Zhao WH, Wang BY, Chen LJ, Fu WJ, Xu J, Liu J, Jin SW, Chen YX, Cao XM, Yang Y, Zhang YL, Wang FX, Zhang PY, Lei B, Gu LF, Wang JL, Zhang H, Bai J, Xu Y, Zhu H, Du J, Jiang H, Fan XH, Li JY, Hou J, Chen Z, Zhang WG, Mi JQ, Chen SJ, He AL. Zhao WH, et al. J Hematol Oncol. 2022 Jul 6;15(1):86. doi: 10.1186/s13045-022-01301-8. J Hematol Oncol. 2022. PMID: 35794616 Free PMC article. Clinical Trial.
METHODS: LEGEND-2 was a phase 1, single-arm, open-label study conducted in four registered sites in China. Seventy-four participants with RRMM received LCAR-B38M treatment. ...Four patients experienced viral infection more than 6 months post-infusion, and four patients dev …
METHODS: LEGEND-2 was a phase 1, single-arm, open-label study conducted in four registered sites in China. Seventy-four participants …
Understanding the increasing incidence of neuroendocrine tumors.
Pathak S, Starr JS, Halfdanarson T, Sonbol MB. Pathak S, et al. Expert Rev Endocrinol Metab. 2023 Sep-Nov;18(5):377-385. doi: 10.1080/17446651.2023.2237593. Epub 2023 Jul 19. Expert Rev Endocrinol Metab. 2023. PMID: 37466336 Review.
INTRODUCTION: Neuroendocrine tumors (NETs) are a diverse group of tumors with origins from different primary sites such as gastro-entero-pancreatic, lung and endocrine tissue. ...EXPERT OPINION: Overall, the incidence of NET has increased across the globe over the l …
INTRODUCTION: Neuroendocrine tumors (NETs) are a diverse group of tumors with origins from different primary sites such as gas …
Metastasising pleomorphic adenoma: Systematic review.
Knight J, Ratnasingham K. Knight J, et al. Int J Surg. 2015 Jul;19:137-45. doi: 10.1016/j.ijsu.2015.04.084. Epub 2015 May 6. Int J Surg. 2015. PMID: 25958295 Free article. Review.
BACKGROUND: Pleomorphic adenoma (PA) is the commonest benign neoplasm of salivary glands.(1) PA can undergo malignant transformation to ex-pleomorphic adenoma (2,3) but rarely, can metastasise without malignant transformation.(4,5) Metastasising pleomorphic a …
BACKGROUND: Pleomorphic adenoma (PA) is the commonest benign neoplasm of salivary glands.(1) PA can undergo malignant transfor …
Multiple malignant tumors.
Chirila DN, Turdeanu NA, Constantea NA, Coman I, Pop T, Popp RA, Balacescu O, Vesa SC, Ciuce C. Chirila DN, et al. Chirurgia (Bucur). 2013 Jul-Aug;108(4):498-502. Chirurgia (Bucur). 2013. PMID: 23958092 Free article.
RESULTS: We included in the present study 217 patients (4.33%) with two or more malignant primary tumors from 5003 cases diagnosed with a primary cancer. The most common sites for multiple malignant tumors were related to the breast, colo …
RESULTS: We included in the present study 217 patients (4.33%) with two or more malignant primary tumors from 5003 cases diagn …
A Review of the Aetiopathogenesis and Clinical and Histopathological Features of Oral Mucosal Melanoma.
Feller L, Khammissa RAG, Lemmer J. Feller L, et al. ScientificWorldJournal. 2017;2017:9189812. doi: 10.1155/2017/9189812. Epub 2017 May 30. ScientificWorldJournal. 2017. PMID: 28638859 Free PMC article. Review.
In most cases, oral mucosal melanoma arises from epithelial melanocytes in the basal layer of the epithelium and less frequently from immature melanocytes arrested in the lamina propria. In both cases the melanocytes undergo malignant transformation, invade deeper tissues, …
In most cases, oral mucosal melanoma arises from epithelial melanocytes in the basal layer of the epithelium and less frequently from immatu …
Melanoma of unknown primary: New perspectives for an old story.
Boussios S, Rassy E, Samartzis E, Moschetta M, Sheriff M, Pérez-Fidalgo JA, Pavlidis N. Boussios S, et al. Crit Rev Oncol Hematol. 2021 Feb;158:103208. doi: 10.1016/j.critrevonc.2020.103208. Epub 2020 Dec 28. Crit Rev Oncol Hematol. 2021. PMID: 33383207 Review.
Spontaneous regression of the primary lesion is a well-established theory, based on the evidence that melanoma can undergo regression at the primary site. MUP and stage-matched melanoma of known primary site (MKP) share similar prognostic factors. The …
Spontaneous regression of the primary lesion is a well-established theory, based on the evidence that melanoma can undergo regression …
Diagnostic and therapeutic management of cancer of an unknown primary.
Pavlidis N, Briasoulis E, Hainsworth J, Greco FA. Pavlidis N, et al. Eur J Cancer. 2003 Sep;39(14):1990-2005. doi: 10.1016/s0959-8049(03)00547-1. Eur J Cancer. 2003. PMID: 12957453 Review.
Metastatic Cancer of Unknown Primary Site (CUP) accounts for approximately 3% of all malignant neoplasms and is therefore one of the 10 most frequent cancer diagnoses in man. ...The following clinicopathological entities have been recognised: (i) metastatic C …
Metastatic Cancer of Unknown Primary Site (CUP) accounts for approximately 3% of all malignant neoplasms and is therefo …
1,281 results